Genuine Biotech

About Genuine Biotech

Genuine Biotech is an R&D-driven biopharmaceutical company focused on developing, manufacturing, and commercializing drugs for viral infections, oncology, and cardio-cerebrovascular diseases. Founded in 2012 by Wang Zhaoyang, the company is headquartered in Pingdingshan, China, with a comprehensive industrial layout that includes R&D centers in Shenzhen and Shanghai, clinical and marketing teams in Beijing, and a GMP-compliant manufacturing facility in Pingdingshan.

The company's mission is to address unmet medical needs by tackling drug resistance in existing treatments. Genuine Biotech's core product is Azvudine, a Class 1.1 innovative drug. It is the world's first dual-target inhibitor of nucleoside reverse transcriptase and Vif for treating HIV infection. Azvudine was also the first oral antiviral for COVID-19 developed by a Chinese company to receive conditional approval from the NMPA in July 2022 and has been included in the National Reimbursement Drug List of China. The company has formed a strategic partnership with Fosun Pharmaceutical Industrial to commercialize Azvudine.

Genuine Biotech's pipeline includes dosimertinib for non-small cell lung cancer and CL-197, a new-generation oral long-acting HIV candidate. The company leverages several technology platforms, including those for highly selective nucleoside broad-spectrum anti-tumor drug R&D and innovative drug design. The business model integrates R&D, manufacturing, sales, and clinical management. The company has successfully raised significant capital, including a Series B financing round of approximately $100 million in 2022, to fuel its clinical trials and the commercialization of its products.